Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$23.98
-2.6%		$29.28
$4.97
▼
$45.50
$174.20M2.47218,056 shs177,339 shs
Generation Bio Co. stock logo
GBIO
Generation Bio
$5.34
$5.48
$3.00
▼
$6.95
$35.99M2.05160,744 shsN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.34
+0.9%		$4.94
$2.33
▼
$8.51
$142.02M1.79218,755 shs38,690 shs
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
$1.29
-6.5%		$2.35
$0.92
▼
$8.57
$171.88M1.18777,518 shs1.13 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
0.00%-29.88%-27.53%+11.69%-96.70%
Generation Bio Co. stock logo
GBIO
Generation Bio
0.00%0.00%0.00%0.00%-14.56%
Oncocyte Corp stock logo
IMDX
Oncocyte
0.00%+0.46%-12.50%-28.74%+433,999,900.00%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
0.00%+20.56%-53.43%+5.74%-82.61%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$23.98
-2.6%		$29.28
$4.97
▼
$45.50
$174.20M2.47218,056 shs177,339 shs
Generation Bio Co. stock logo
GBIO
Generation Bio
$5.34
$5.48
$3.00
▼
$6.95
$35.99M2.05160,744 shsN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.34
+0.9%		$4.94
$2.33
▼
$8.51
$142.02M1.79218,755 shs38,690 shs
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
$1.29
-6.5%		$2.35
$0.92
▼
$8.57
$171.88M1.18777,518 shs1.13 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
0.00%-29.88%-27.53%+11.69%-96.70%
Generation Bio Co. stock logo
GBIO
Generation Bio
0.00%0.00%0.00%0.00%-14.56%
Oncocyte Corp stock logo
IMDX
Oncocyte
0.00%+0.46%-12.50%-28.74%+433,999,900.00%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
0.00%+20.56%-53.43%+5.74%-82.61%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
1.00
SellN/AN/A
Generation Bio Co. stock logo
GBIO
Generation Bio
2.17
Hold$8.5059.18% Upside
Oncocyte Corp stock logo
IMDX
Oncocyte
2.33
Hold$10.50141.94% Upside
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest GBIO, CUE, INDP, and IMDX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/18/2026
Oncocyte Corp stock logo
IMDX
Oncocyte
Needham & Company LLC logo
Needham & Company LLC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$9.00
8/13/2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/17/2026
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/24/2026
Oncocyte Corp stock logo
IMDX
Oncocyte
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
(Data available from 8/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
$27.47M6.34N/AN/A$0.32 per share74.94
Generation Bio Co. stock logo
GBIO
Generation Bio
$19.89M1.81N/AN/A$12.91 per share0.41
Oncocyte Corp stock logo
IMDX
Oncocyte
$4.05M35.06N/AN/A($0.65) per share-6.68
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/A$0.09 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$26.60M-$27.02N/AN/AN/A-435.83%-620.06%-291.15%N/A
Generation Bio Co. stock logo
GBIO
Generation Bio
-$131.67M-$9.34N/AN/AN/A-410.13%-94.82%-34.13%N/A
Oncocyte Corp stock logo
IMDX
Oncocyte
-$50.22M-$1.49N/AN/AN/A-2,955.63%N/A-107.52%N/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$20.85M-$6.33N/AN/AN/AN/A-302.89%-203.49%N/A

Latest GBIO, CUE, INDP, and IMDX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2026Q2 2026
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
-$1.69-$24.14-$22.45-$24.14$3.00 million$7.88 million
8/13/2026Q2 2026
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
-$1.57-$0.02+$1.55-$0.02N/AN/A
8/10/2026Q2 2026
Oncocyte Corp stock logo
IMDX
Oncocyte
N/A-$0.23N/A-$0.31N/A$0.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/AN/AN/AN/AN/A
Generation Bio Co. stock logo
GBIO
Generation Bio
N/AN/AN/AN/AN/A
Oncocyte Corp stock logo
IMDX
Oncocyte
N/AN/AN/AN/AN/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
N/A
1.25
3.57
Generation Bio Co. stock logo
GBIO
Generation Bio
N/A
4.44
4.44
Oncocyte Corp stock logo
IMDX
Oncocyte
N/A
2.00
1.98
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
N/A
19.49
19.49

Institutional Ownership

CompanyInstitutional Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
35.04%
Generation Bio Co. stock logo
GBIO
Generation Bio
95.22%
Oncocyte Corp stock logo
IMDX
Oncocyte
55.35%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
7.06%

Insider Ownership

CompanyInsider Ownership
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
14.56%
Generation Bio Co. stock logo
GBIO
Generation Bio
21.10%
Oncocyte Corp stock logo
IMDX
Oncocyte
2.21%
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
9.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
Cue Biopharma, Inc. stock logo
CUE
Cue Biopharma
607.26 million6.21 millionOptionable
Generation Bio Co. stock logo
GBIO
Generation Bio
1506.74 million5.32 millionOptionable
Oncocyte Corp stock logo
IMDX
Oncocyte
12032.72 million32.00 millionN/A
Indaptus Therapeutics, Inc. stock logo
INDP
Indaptus Therapeutics
6133.24 million120.00 millionNot Optionable

Recent News About These Companies

Why Indaptus Therapeutics, Inc.’s (INDP) Stock Is Down 10.07%
August 21 at 5:21 PM  |  aaii.comA
Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1%
August 14, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/short-interest-in-indaptus-therapeutics-inc-nasdaqindp-declines-by-641-2026-08-14/
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update
August 13, 2026  |  quiverquant.comQ
Indaptus Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update
August 13, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/08/13/3344352/0/en/indaptus-therapeutics-reports-second-quarter-2026-financial-results-and-provides-corporate-update.html
Indaptus Therapeutics (INDP) to Announce Earnings on Monday
August 10, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/indaptus-therapeutics-indp-to-announce-earnings-on-monday-2026-08-10/
Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Up 88.8% in July
July 30, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/indaptus-therapeutics-inc-nasdaqindp-short-interest-up-888-in-july-2026-07-30/
Indaptus Therapeutics Announces Private Placement of Common Stock
June 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/indaptus-therapeutics-announces-private-placement-of-common-stock?utm_source=marketbeat.com&utm_medium=referral
Abbott Cooper PLLC Announces Investigation on Behalf of Indaptus Therapeutics, Inc. Stockholders
June 17, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/18/3313904/0/en/abbott-cooper-pllc-announces-investigation-on-behalf-of-indaptus-therapeutics-inc-stockholders.html
Indaptus Therapeutics Announces Recent Board and Leadership Changes
June 5, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/indaptus-therapeutics-announces-recent-board-and-leadership-changes?utm_source=marketbeat.com&utm_medium=referral
Indaptus Therapeutics (INDP) jumps 53.8% amid heavy volume as investors focus on financing/strategic-option uncertainty
June 4, 2026  |  quiverquant.comQ
Indaptus Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/15/3295732/0/en/indaptus-therapeutics-reports-first-quarter-2026-financial-results-and-provides-corporate-update.html
Indaptus Therapeutics Adds Independent Directors Amid Board Refresh
April 23, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/indaptus-therapeutics-adds-independent-directors-amid-board-refresh?utm_source=marketbeat.com&utm_medium=referral
Indaptus Therapeutics Appoints David Natan to Board
January 8, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/indaptus-therapeutics-appoints-david-natan-to-board?utm_source=marketbeat.com&utm_medium=referral
Biolojic Design appoints new chief medical officer
January 8, 2026  |  thepharmaletter.comT
Indaptus Therapeutics announces upcoming board leadership transition
January 3, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/indaptus-therapeutics-announces-upcoming-board-leadership-transition/ar-AA1TtDQN
Indaptus Therapeutics enters $6M securities purchase agreement with David Lazar
December 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/companies/indaptus-therapeutics-enters-6m-securities-purchase-agreement-with-david-lazar/ar-AA1TdUy1
Indaptus Therapeutics stock falls after $6 million securities deal
December 29, 2025  |  za.investing.comhttps://za.investing.com/news/stock-market-news/indaptus-therapeutics-stock-falls-after-6-million-securities-deal-93CH-4041734
Why did INDP stock gain 12% today?
December 29, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/why-did-indp-stock-gain-12-today/ar-AA1TdhWI
Indaptus Therapeutics Secures $6 Million Investment from David E. Lazar, Appoints Him Co-CEO and Chairman
December 29, 2025  |  quiverquant.comQ
Indaptus Enters Into $6 Million Securities Purchase Agreement with Investor David E. Lazar
December 29, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/12/29/3210857/0/en/indaptus-enters-into-6-million-securities-purchase-agreement-with-investor-david-e-lazar.html
Indaptus Therapeutics (INDP) Price Target Decreased by 60.00% to 10.20
November 17, 2025  |  msn.comhttps://www.msn.com/en-us/money/topstocks/indaptus-therapeutics-indp-price-target-decreased-by-6000-to-1020/ar-AA1QDgia

New MarketBeat Followers Over Time

Media Sentiment Over Time

Cue Biopharma stock logo

Cue Biopharma NASDAQ:CUE

$23.98 -0.63 (-2.56%)
As of 08/21/2026 04:00 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

Generation Bio stock logo

Generation Bio NASDAQ:GBIO

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Oncocyte stock logo

Oncocyte NASDAQ:IMDX

$4.34 +0.04 (+0.93%)
As of 08/21/2026 04:00 PM Eastern

OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.

Indaptus Therapeutics stock logo

Indaptus Therapeutics NASDAQ:INDP

$1.29 -0.09 (-6.52%)
As of 08/21/2026 04:00 PM Eastern

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas